GBT:EPA
Guerbet SA
€6.65
arrow_downward
-0.45%(-0.030) 1D
Oct 5, 5:35:14 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GBT...
Open
€6.62
High
€6.70
Low
€6.62
Mkt. cap
81.41M
Avg. vol.
10.89K
Volume
0.00
52-wk high
€18.26
52-wk low
€6.60
EPS
-€11.05
Shares outstanding
12.64M
No. of employees
3K
Open
€6.62
High
€6.70
Low
€6.62
Mkt. cap
81.41M
Avg. vol.
10.89K
Volume
0.00
52-wk high
€18.26
52-wk low
€6.60
EPS
-€11.05
Shares outstanding
12.64M
No. of employees
3K
News stories
From web sources and news partners
Simply Wall Street
·
52 minutes ago
Legend Biotech (LEGN) Could Be 60% Undervalued On Fresh CARVYKTI Trial Data
The Globe and Mail
·
1 hour ago
The Bond Market Just Sent Investors a Warning. Here's the Mistake I'd Avoid Making With the S&P 500.
Simply Wall Street
·
52 minutes ago
Does One Year DM1 Trial Data Change The Bull Case For Dyne Therapeutics Stock?
Profile
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in over 20 countries including France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters is located in Villepinte, Seine-Saint-Denis.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product is produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories. Wikipedia
About Guerbet SA